Personalis, Inc.

PSNL
About the company

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.

Country: United StatesPrice: $15.71Market Cap: $1.7B

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

1 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2295 (Top 74.1%)PASSFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: -684.0x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities4.53
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-684.0x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0043; #485/4210 (top 11.5%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Profitability0% pass✓ 3✗ 32▾

    No clean pass — all 16 investors flag at least one profitability criterion

    Positive EPS (10 years)0/10 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/10 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-45.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-126.4% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-75.7M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-56.1%
    ✗Lynch> 15%
    EBIT / Enterprise Value-5.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-5.6%, ROC=-59.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-24.32%
    ✗PiotroskiROA > 0
    ROA Change YoY-30.08% -> -24.32% (delta: +5.75%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-22.43%, ROA=-24.32%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY31.7% -> 22.7%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-147.7%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-56.1%
    ✗Dreman> 12%
    Margin of SafetyP/B=6.2x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-51.6% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-156.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-56.1%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-149.6% (2023) -> -126.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 24.8% -> 22.7%, operating margin -149.6% -> -126.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-7.01%; #4018/6340 (top 63.4%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+4.72%; #3110/3702 (top 84.0%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-56.11%; #4286/5226 (top 82.0%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1103; #3599/5884 (top 61.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/9 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio6.2x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-5.6%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-5.6%, ROC=-59.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share6.2x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-4.7%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-4.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=6.2x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low448% of trailing low ($3.51)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-7.01%; #4018/6340 (top 63.4%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1249; #4608/6449 (top 71.5%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share6.16x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.0474; #4591/5247 (top 87.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-6.32%; #3057/4519 (top 67.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+184.60%; #162/6202 (top 2.6%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-75.7M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-107.7M
    ✗LynchPositive and growing
    Operating Cash Flow$-74.9M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-22.43%, ROA=-24.32%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-4.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/9 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-6.7%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency2/9 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-107.7M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-6.32%; #3057/4519 (top 67.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthN/A (no inventory)
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/9 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth13.0%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 24.8% -> 22.7%, operating margin -149.6% -> -126.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-2.4%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts6% pass✓ 1✗ 15▾

    Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)✗GreenblattRank #2295✓PiotroskiPASS (F-Score 4)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1691/2370 (Top 71.4%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag PSNL's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio4.53
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-61.9%
    ✗Buffett> 10%
    ROIC - WACC-71.9%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-59.1%
    ✗Greenblatt> 25%
    Current Ratio Change YoY6.52 -> 6.76
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.31x -> 0.21x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities4.53
    ✓Dreman> 1.5
    Return on Invested Capital-46.8%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-66.3%; FY2024: ROIC=-26.4%; FY2025: ROIC=-26.5%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -26.5%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Healthcare
SIC Sector: Health Services
Size: Small Cap($1.7B)
Revenue: $69.6M-17.7% YoY
Net Income: $81.3M+0.0% YoY

Financial Snapshot

Operating Margin-126.4%
Return on Equity-31.1%
Debt / Equity0.01
Current Ratio6.76
EPS (Diluted)$-0.91
Shares Retired−20.3%

Similar Companies

HCAHCA Healthcare, Inc.
$104.2B
THCTENET HEALTHCARE CORP
$22.8B
GHGuardant Health, Inc.
$20.5B
EXASEXACT SCIENCES CORP
$20.0B

Shareholder Return

Fiscal 2025

Issued 20.3% of shares last year.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-26
FY 2024
Sources
  • 10-K · 2025-02-27
FY 2023
Sources
  • 10-K · 2024-02-28
FY 2022
Sources
  • 10-K · 2023-02-23
FY 2021
Sources
  • 10-K · 2022-02-24
Market Cap$1.7Bcurrent------$960.2Mest.$444.6Mest.$67.7Mest.$109.8Mest.$512.0Mest.
Revenue$80.8M↑17%$25.6M↑77%$22.4M↑30%$15.5M↓25%$69.6M↓18%$84.6M↑15%$73.5M↑13%$65.0M↓24%$85.5M
Operating Income-$126.5M↓56%-$35.5M↓52%-$33.6M↓54%-$32.2M↓82%-$88.1M↓29%-$68.3M↑38%-$109.9M↑5%-$115.5M↓77%-$65.4M
Net Income-$119.3M↓62%-$33.8M↓56%-$31.7M↓58%-$30.0M↓91%-$81.3M-$81.3M↑25%-$108.3M↑4%-$113.3M↓74%-$65.2M
EPS (Diluted)--$-0.32↓33%$-0.30↓30%$-0.29↓61%$-0.91↑34%$-1.37↑39%$-2.25↑9%$-2.48↓66%$-1.49
Gross Margin————22.7%↓29%31.7%↑28%24.8%↑21%20.5%↓45%37.0%
Operating Margin-156.7%↓34%-138.8%↑14%-150.2%↓19%-207.9%↓142%-126.4%↓57%-80.7%↑46%-149.6%↑16%-177.6%↓132%-76.4%
ROE-56.1%↓30%———-31.1%↑22%-40.0%↑52%-83.7%↓61%-51.9%↓147%-21.0%
Total Debt$918.0K↓71%$918.0K↓71%$898.0K↓52%$1.1M↓61%$1.8M↑9%$1.7M↑1%$1.6M↓26%$2.2M↑23%$1.8M
Shareholders' Equity$212.7M↑24%$212.7M↑24%$235.2M↑23%$254.8M↑23%$261.2M↑29%$203.0M↑57%$129.4M↓41%$218.1M↓30%$310.3M
Current Ratio4.53↓6%4.53↓6%5.28↓13%6.61↓4%6.76↑4%6.52↑110%3.11↓48%6.03↓41%10.16
Debt / Equity0.00↓77%0.00↓77%0.00↓61%0.00↓68%0.01↓16%0.01↓35%0.01↑25%0.01↑75%0.01
Operating Cash Flow-$97.6M↓61%-$27.1M↓24%-$25.8M↓99%-$22.5M↓25%-$74.9M↓66%-$45.1M↑20%-$56.3M↑20%-$70.2M↑1%-$70.8M
Free Cash Flow-$107.7M↓63%-$30.1M↓29%-$29.6M↓123%-$25.7M↓25%-$79.5M↓70%-$46.8M↑30%-$67.2M↑44%-$120.1M↓47%-$81.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Healthcare

PSNL vs Peers — Financial Grading

Revenue$69.6MBottom 25%
Net Income$81.3MBottom 25%
ROE-31.1%Bottom 25%
D/E0.01Median
Op. Margin-126.4%Bottom 25%
Curr. Ratio6.76Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
HCA Healthcare, Inc.HCA$104.2B$499.05$75.6B$6.8B-112.6%-7.7113.0%0.971/95/93/71/3F-Score 64/11
TENET HEALTHCARE CORPTHC$22.8B$286.03$21.3B$2.4B56.1%3.1216.5%1.761/94/93/73/3F-Score 65/11
Guardant Health, Inc.GH$20.5B$151.70$982.0M$416.3M419.2%-15.14-44.5%4.842/91/91/70/3F-Score 52/11
EXACT SCIENCES CORPEXAS$20.0B$104.91$3.2B$207.9M-8.7%0.00-6.4%2.432/91/93/70/3F-Score 73/11
Fresenius Medical Care AGFMS$11.4B$22.03$23.1B$1.1B7.4%0.819.3%1.265/92/91/70/3F-Score 85/11
UNIVERSAL HEALTH SERVICES INCUHS$11.2B$194.07$17.4B$1.5B20.5%0.6511.5%1.054/96/95/71/3F-Score 76/11
DAVITA INC.DVA$11.0B$174.56$13.6B$746.8M-114.7%-15.7815.0%1.291/94/92/71/3F-Score 73/11
CHEMED CORPCHE$7.1B$548.20$2.5B$265.2M27.1%—13.4%1.054/97/93/71/3F-Score 66/11